Secondary Logo

Institutional members access full text with Ovid®

Pneumocystis Infection in Children

National Trends and Characteristics in the United States, 1997–2012

Inagaki, Kengo, MD*; Blackshear, Chad, MS; Hobbs, Charlotte V., MD*

The Pediatric Infectious Disease Journal: March 2019 - Volume 38 - Issue 3 - p 241–247
doi: 10.1097/INF.0000000000002119
Original Studies
Buy
SDC

Background: Although the epidemiology of immunocompromising condition in children has evolved over time, updated epidemiology of pediatric pneumocystis infection in the United States is not available.

Methods: We performed a retrospective analysis using the Kids’ Inpatient Database, a nationally representative sample of US pediatric hospital discharges collected in 1997, 2000, 2003, 2006, 2009 and 2012. Pneumocystis cases were identified using International Classification of Diseases, Ninth Revision, Clinical Modification, code 136.3 among children 0–18 years of age. Demographic data of cases with and without mortality were compared.

Results: We identified 1902 [standard error (SE): 95] pneumocystis cases during the study period. The pneumocystis hospitalization rate decreased from 7.5 (SE: 0.91) to 2.7 (SE: 0.31) per a million US children from 1997 to 2012 (63.2% decrease). Cases with HIV infection decreased from 285 (SE: 56) cases in 1997 to 29 (SE: 7) cases in 2012, whereas hematologic malignancy and primary immunodeficiency became more prominent. Infants were the most commonly affected [510 cases (SE: 40)]. All-cause in-hospital mortality was 11.7% (SE: 1.3%) and was particularly high among cases with hematopoietic stem cell transplant [32.4%(SE: 7.1%); P < 0.001].

Conclusions: Pneumocystis infection in children showed a marked decrease from 1997 to 2012 in the United States, largely driven by the reduction in HIV-associated cases, and cases with non-HIV illnesses became more prominent. Hematopoietic stem cell transplant–associated cases had particularly high mortality. Clinicians should be aware of high-risk groups that may benefit from chemoprophylaxis, particularly in infancy.

*Department of Pediatrics

Department of Data Science, University of Mississippi Medical Center, Jackson, Mississippi.

Accepted for publication May 6, 2018.

The authors have no funding or conflicts of interest to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).

Address for correspondence: Kengo Inagaki, MD, Department of Pediatrics, University of Mississippi Medical Center, 2500 N State St, Jackson, MS 39216. E-mail: kinagaki@umc.edu.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.